Rebinyn® successfully protected patients from bleeds during all major surgeries studied.
aIn a pharmacokinetic assessment of a single dose of Rebinyn® 40 IU/kg upon enrollment in two phase 3 studies, factor levels were evaluated for 1 week after the first dose of Rebinyn® 40 IU/kg. The average levels after 7 days were 16.8% in 6 adults, 14.6% in 3 adolescents, 10.9% in 13 children aged 7 to 12 years, and 8.4% in 12 children up to age 6 years.
EXPERIENCE HIGH FACTOR LEVELS
With a single dose of Rebinyn® 40 IU/kg, adults with less than or equal to 2% Factor 9 levels experienced:
![Percentage of factor levels achieved after an infusion and Percentage of mean factor levels sustained](/content/dam/biopharm/rebinyn/reliable-bleed-control/adult-factor-levels.png)
![Percentage of factor levels achieved after an infusion](/content/dam/biopharm/rebinyn/reliable-bleed-control/94-percent-adult.png)
![Percentage of mean factor levels sustained](/content/dam/biopharm/rebinyn/reliable-bleed-control/17-percent-adult.png)
bBased upon a 2.34% increase in factor levels per IU/kg infused in adults receiving a single dose of Rebinyn® 40 IU/kg.
A single dose of Rebinyn® 40 IU/kg was shown to elevate factor levels above their normal levels in pediatric patients.b
In children up to
6 years of age
![Statistic on factor levels in children up to 6 years of age](/content/dam/biopharm/rebinyn/reliable-bleed-control/children-6yrs.png)
In children ages
7-12 years
![Statistic on factor levels in children ages 7-12 years](/content/dam/biopharm/rebinyn/reliable-bleed-control/children-7-12yrs.png)
In adolescents ages
13-17 years
![Statistic on factor levels in adolescents ages 13-17](/content/dam/biopharm/rebinyn/reliable-bleed-control/adolesence-13-17yrs.png)
bBased on pharmacokinetic assessment of a single dose of Rebinyn® 40 IU/kg after 7 days in 3 adolescents (mean FIX activity 14.6%), 13 children aged 7 to 12 (mean FIX activity 10.9%), and 12 children aged 0-6 (mean FIX activity 8.4%) upon enrollment in the phase 3 trials using 1-stage assay and product-specific standard. All values are geometric mean.
cBased upon a 1.51% increase in factor levels per IU/kg infused in children aged ≤6 receiving a single dose of Rebinyn® 40 IU/kg.
dBased upon a 1.59% increase in factor levels per IU/kg infused in children aged 7-12 receiving a single dose of Rebinyn® 40 IU/kg.
eBased upon a 1.96% increase in factor levels per IU/kg infused in adolescents aged 13-17 receiving a single dose of Rebinyn® 40 IU/kg.
![Average half-life in adults at 3.5 days](/content/dam/biopharm/rebinyn/preventing-bleeds/1.1-83-half-life.png)
Timothy has severe hemophilia B and uses Rebinyn®.
![Timothy smiling on a sailing boat](/content/dam/biopharm/rebinyn/reliable-bleed-control/callout-mobile.png)
![Average half-life in adults at 3.5 days](/content/dam/biopharm/rebinyn/preventing-bleeds/1.1-83-half-life.png)
DID YOU KNOW?
Half-life is the time it takes for the level of factor in the blood to fall by half (50%).
![Did you know? Half-life fact](/content/dam/biopharm/rebinyn/reliable-bleed-control/did-you-know-white.png)
LOOKING FOR RELIABILITY IN YOUR FACTOR 9 TREATMENT?
![](/content/dam/biopharm/rebinyn/global/line.png)
A study of adults and adolescents with hemophilia B showed that Rebinyn® on demand treated 98% of bleeds with 1-2 infusions.f In another study, bleed control was rated successful (defined as excellent or good) in 95% of 142 bleeding episodes.g
![Percentage of bleeds treated with 1-2 infusions and Percentage of hemophilia B patients that rated their bleed control as successful](/content/dam/biopharm/rebinyn/reliable-bleed-control/98-95-group.png)
![Percentage of bleeds treated with 1-2 infusions](/content/dam/biopharm/rebinyn/reliable-bleed-control/98-card.png)
![Percentage of hemophilia B patients that rated their bleed control as successful](/content/dam/biopharm/rebinyn/reliable-bleed-control/95-card.png)
fResults shown are from the on-demand arm of the adolescent/adult clinical study in previously treated patients. In this study, 15 people were treated for on-demand bleeds. In 14 people, there were a total of 143 bleeding episodes.
gResults shown are based on a bleed assessment by either the patient (for home treatment) or the study investigator (for treatment under medical supervision). Bleeds were assessed using a 4-point scale of excellent, good, moderate, or poor.
![Markus by the beach Markus looking off into the distance](/content/dam/biopharm/rebinyn/reliable-bleed-control/markus-simple-dosing.png)
PROTECTION IN SURGERY
![](/content/dam/biopharm/rebinyn/global/line-50.png)
PREVENT BLEEDS WITH PROPHYLAXIS
Learn what once-weekly Rebinyn® can do for you.
![Calendar with check marks](/content/dam/biopharm/rebinyn/higher-factor-levels/calendar.jpg)
HOW IT EXTENDS HALF-LIFE
Rebinyn® uses technology that helps it stay in your body longer, to protect you longer.
![extended half-life icon](/content/dam/biopharm/rebinyn/global/extends-half-life-cta.png)